Physician profile
Paul Milner
NPI 1356339782
$2,538.65
in general payments reported to CMS, 2019-2025
23 companies · $466 in 2025
The $466 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $114 · 2021: $325 · 2022: $537 · 2023: $391 · 2024: $280 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $758.21 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $644.02 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $396.39 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $170.87 | 2022-2025 | Ocaliva |
| Pfizer INC. | $131.71 | 2019-2020 | |
| Celgene Corporation | $61.20 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $59.01 | 2023-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $52.89 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $50.74 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $31.49 | 2025 | Iqirvo |
| Genzyme Corporation | $27.33 | 2024 | |
| Qol Medical, LLC | $18.07 | 2024 | Sucraid |
| Alnylam Pharmaceuticals INC. | $17.12 | 2022 | |
| Lilly USA, LLC | $16.87 | 2025 | Omvoh |
| Endogastric Solutions, INC | $15.95 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14.98 | 2025 | Saxenda, Wegovy |
| Alexion Pharmaceuticals, INC. | $12.54 | 2019 | |
| Ardelyx, INC. | $12.31 | 2022 | |
| Janssen Biotech, INC. | $12.22 | 2019 | |
| Allergan, INC. | $11.98 | 2019 | |
| Shire North American Group INC | $11.85 | 2019 | |
| Ironwood Pharmaceuticals, INC | $10.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,139.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Milner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.